CTA submission for PN6047
PharmNovoAB is pleased to announce that the clinical trial application (CTA) for a PhaseIIa proof of concept (PoC) study investigating the safety and efficacy of leadcandidate PN6047 in patients with neuropathic pain has been submitted in Spain.The full title of the application is: “Randomized Double-BlindPlacebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacyof PN6047 HCl in Peripheral Neuropathic Pain Characterized by MechanicalAllodynia.”
Based on astrategic company decision, PharmNovo has submitted the CTA, in the firstinstance, to the Spanish Health Authorities only. Submission to the CzechRepublic and Poland, the two other countries in which the trial will beconducted, is planned to take place following approval in Spain, which isexpected by October 2025. Subject to additional investment, patient enrolmentis expected to start by Quarter 1 2026.
CTA submission for PN6047
PharmNovoAB is pleased to announce that the clinical trial application (CTA) for a PhaseIIa proof of concept (PoC) study investigating the safety and efficacy of leadcandidate PN6047 in patients with neuropathic pain has been submitted in Spain.The full title of the application is: “Randomized Double-BlindPlacebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacyof PN6047 HCl in Peripheral Neuropathic Pain Characterized by MechanicalAllodynia.”
Based on astrategic company decision, PharmNovo has submitted the CTA, in the firstinstance, to the Spanish Health Authorities only. Submission to the CzechRepublic and Poland, the two other countries in which the trial will beconducted, is planned to take place following approval in Spain, which isexpected by October 2025. Subject to additional investment, patient enrolmentis expected to start by Quarter 1 2026.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
